Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II topical rapamycin for facial angiofibromas in tuberous sclerosis complex
2011-006308-12Phase 2Active
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in facial angiofibroma and tuberous sclerosis complex (TSC), sponsored by Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal. Primary endpoint: Clinical success at 3 months. Started Mar 2012; status: active.
02
Drugs
sirolimus
03
Conditions
facial angiofibromatuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2011-006308-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006308-12.